1-4 of 4
JingJing Cao
Close
Sort by
Journal Articles

Effect of Ivospemin and Difluoromethylornithine Polyamine Inhibitors on Viability of Myeloma Cell Lines

Abdur Rehman, Lubna Rehman, Krish Devnani, Cao Cuong Le, Chun-Yen Lin, Xiayoun Cheng, Fuliang Chu, Jinsheng Weng, Jingwei Liu, Sridevi Patchva, Shao-Qing Kuang, Jingjing Cao, Matthew Richard, Elizabeth Bruckheimer, Sattva S. Neelapu, Neeraj Y. Saini
Journal: Blood
Blood (2023) 142 (Supplement 1): 6589.
https://doi.org/10.1182/blood-2023-189595
Published: 2023
Journal Articles

Targeting B-Cell Malignancies with Anti-ROR1 CAR T-Cell Therapy

Jinsheng Weng, Cao Cuong Le, Yong Pan, Francesca Perutelli, Xiaoyun Cheng, Jingjing Cao, Owhofasa Agbedia, Shao-Qing Kuang, Jingwei Liu, Fuliang Chu, Sridevi Patchva, Neeraj Y. Saini, Sattva S. Neelapu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6827.
https://doi.org/10.1182/blood-2023-180028
Published: 2023
Journal Articles

Targeting CAR T Resistance Due to CD19 Loss with CD79b-Specific CAR T Cells in B-Cell Malignancies

Fuliang Chu, PhD, Jinsheng Weng, MD PhD, Shao-Qing Kuang, PhD, Xiaoyun Cheng, JingJing Cao, Jingwei Liu, MD, Swathi Karri, Adithi Reddy, Sattva S. Neelapu, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1662.
https://doi.org/10.1182/blood-2018-99-119009
Published: 2018
Journal Articles

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Loretta Nastoupil, MD, Jason R. Westin, MD, Nathan H. Fowler, MD, Michelle A. Fanale, MD, Felipe Samaniego, MD, Yasuhiro Oki, MD, Ly Dsouza, PA-C, Chizobam Obi, RN, JingJing Cao, Xiaoyun Cheng, Man Chun John MA, PhD, Wang Zhiqiang, Lei Feng, MS, Shouhao Zhou, R. Eric Davis, MD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 414.
https://doi.org/10.1182/blood.V130.Suppl_1.414.414
Published: 2017